热门资讯> 正文

CyclomX Therapeutics推出2.5亿美元公开募股

2026-03-17 04:26

CytomX医疗(CTMX) 0

CytomX Therapeutics (CTMX) has commenced an underwritten public offering of $250M of shares of common stock and pre-funded warrants.
In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock at the public offering price.
CytomX expects to use the net proceeds from this offering for the continued development of Varseta-M and other pipeline programs. CytomX expects to use any remaining net proceeds from this offering for capital expenditures, working capital, and other general corporate purposes.
CTMX -1.48% after hours to $6.65.
Source: Press Release

More on CytomX

CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027
CytomX GAAP EPS of -$0.15 misses by $0.12, revenue of $76.2M misses by $6.69M

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。